Oxaliplatin LBM

Phase 2Small molecule

IInstitut du Cancer de Montpellier - Val d'Aurelle

Oxaliplatin LBM is one of 48 small molecule programs targeting Chemotherapy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ChemotherapyActive, not recruiting

ChemotherapyPhase 2

Active, not recruiting

Competition

Competitive Landscape

116 competitors in Chemotherapy

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 3

20 2

Eloxatin

Teva

Phase 3

14 3

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

31 4

Avastin

Roche

Phase 3

12 5

Cytosar

Teva

Phase 3

11 6

Imfinzi

AstraZeneca

Phase 3

8 7

Camptosar

Pfizer

Phase 3

8 8

Vepesid

AAvyxa

Phase 3

23 9

Opdivo

Bristol-Myers Squibb

Phase 3

7 10

Beyfortus

BeiGene

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chemotherapy1 trial

LEAn Body Mass Normalization of OXaliplatin Based Chemotherapy

Active, not recruiting·IInstitut du Cancer de Montpellier - Val d'Aurelle·Phase 2·NCT03255434·160 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Oxaliplatin LBM. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Oxaliplatin LBM compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Oxaliplatin LBM. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Institut du Cancer de Montpellier - Val d'Aurelle company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: IInstitut du Cancer de Montpellier - Val d'Aurelle

Oxaliplatin LBM

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chemotherapy1 trial

References

Drug Info

Quick Facts

Related News